Get the Stockscreener App
0.4601
11.65%
0.048
After Hours:
.47
0.0099
+2.15%
Tonix Pharmaceuticals Holding Corp stock is traded at $0.4601, with a volume of 376.18M.
It is up +11.65% in the last 24 hours and up +36.29% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$0.4121
Open:
$0.4432
24h Volume:
376.18M
Relative Volume:
3.37
Market Cap:
$86.35M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-0.0409
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
+92.59%
1M Performance:
+36.29%
6M Performance:
-16.35%
1Y Performance:
-95.27%
1-Day Range:
$0.365
$0.583
1-Week Range:
$0.2375
$0.583
52-Week Range:
$0.118
$12.48
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
0.4601 | 86.35M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.68 | 114.07B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
686.33 | 75.31B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
648.11 | 39.72B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
279.19 | 35.53B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
124.30 | 28.78B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.5%What's Next? - MarketBeat
StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 22.4% HigherWhat's Next? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 13.2%Should You Buy? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 7.6%Should You Buy? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 13.2%Here's Why - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 7.6%Should You Buy? - MarketBeat
Tonix Pharmaceuticals Holding (LTS:0A4T) Liabilities-to-Ass - GuruFocus.com
Tonix Pharmaceuticals Holding (LTS:0A4T) Price-to-Operating-Cash-Flow : (As of Jan. 17, 2025) - GuruFocus.com
FDA accepts Tonix’s NDA for non-opioid fibromyalgia drug TNX-102 SL - MSN
Tonix Pharmaceuticals Holding (LTS:0A4T) Net Income : $-135.25 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Hold Rating from Analysts at StockNews.com - Defense World
Tonix Pharmaceuticals Holding (LTS:0A4T) Altman Z-Score : -14.06 (As of Jan. 16, 2025) - GuruFocus.com
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals Holding (LTS:0A4T) 9-Day RSI : N/A (As of Jan. 15, 2025) - GuruFocus.com
Rivoluzionare la salute con i virus? Una nuova era per le scoperte biotecnologiche - Be3
(TNXP)Analyzing Tonix Pharmaceuticals's Short Interest - Benzinga
Revolutionizing Health with Viruses? A New Age for Biotech Breakthroughs - Be3
Tonix Pharmaceuticals Further Strengthens Commercial - GlobeNewswire
Tonix Pharma Announces Key Appointment and Study Timelines - TipRanks
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access - The Manila Times
Tonix Pharmaceuticals Strengthens Commercial Team Ahead of Critical FDA Decision on Fibromyalgia Drug - StockTitan
Tonix Is A Buy For Potentially Great Return On PTSD Breakthrough, Part 2 (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 7.2%Time to Sell? - MarketBeat
Tonix Pharmaceuticals Holding Corp at SNN Planet MicroCap Showcase Transcript - GuruFocus.com
Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences - The Manila Times
Tonix Pharmaceuticals CEO to Present Pipeline Updates at Major Neuroscience and Biotech Forums - StockTitan
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 2.5%Time to Buy? - MarketBeat
SABBY MANAGEMENT, LLC Acquires 1,306,313 Shares in Tonix Pharmaceuticals Holding Corp - GuruFocus.com
What’s Next for TNXP? The Future of Biotech and Stock Surges - Be3
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.5%What's Next? - MarketBeat
Tonix Receives PDUFA Goal Date for Sleep-Enhancing Fibromyalgia Drug Candidate - Sleep Review
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 4.5%What's Next? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 8.4%Time to Sell? - MarketBeat
Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024 - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by StockNews.com - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 7.8%Should You Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 5.3%What's Next? - MarketBeat
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 151.6% in December - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 8.7%Time to Sell? - MarketBeat
This Micro Cap Is Getting Bid Up Prior To Opening Bell - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 2.6%Should You Sell? - MarketBeat
Certain Options of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com
Certain Warrants of Tonix Pharmaceuticals Holding Corp. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 4.4%Time to Sell? - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.2%What's Next? - MarketBeat
FDA sets review goal date for Tonix fibromyalgia drug By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 26.8%Should You Sell? - MarketBeat
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.14%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):